Latest News & Features
Big Pharma
This year’s Life Sciences Law Forum is taking place on June 25 in London. LSIPR caught up with the conference’s chair James Horgan, of Merck Sharp & Dohme, and GlaxoSmithKline counsel Anthony Kenny to find out what’s keeping them busy and what they’ll discuss on the day. 16 June 2015
Americas
As far we know, the IP chapter in the proposed Trans-Pacific Partnership agreement contains provisions on modernising plant breeders’ rights, but not all the participating countries are currently on the same page, as LSIPR reports. 16 June 2015
article
Nearly three years after the introduction of the inter partes review, LSIPR explores its impact on the life sciences sector and asks whether it is creating a culture of ‘reverse trolling’. 16 June 2015
Big Pharma
How will the OECD’s Modified Nexus Approach to innovator-friendly tax regimes such as the UK’s patent box affect the life sciences industry? LSIPR investigates. 16 June 2015
Americas
The antibiotics market could lose out for a decade due to inadequate research and development in the area, according to a report published by UK law firm Marks & Clerk today, June 16. 16 June 2015
Americas
US law firm White and Williams has hired George Xixis as a counsel to its Boston office. 12 June 2015
Americas
LSIPR picks five sessions IP professionals won’t want to miss at this year’s BIO International Convention in Philadelphia, from June 15 to 18. 11 June 2015
Americas
Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more. 11 June 2015
Big Pharma
The English Court of Appeal has issued the latest ruling in the patent dispute between Warner-Lambert and Actavis concerning Lyrica (pregabalin), says Arty Rajendra of Rouse Legal. 11 June 2015
Asia-Pacific
The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17. 11 June 2015